CEPI and IVI renew partnership to accelerate development of vaccines against emerging infectious disease threats
1st September 2023; Oslo, Norway; Seoul, Republic of Korea: The Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) today announced a renewed collaboration to accelerate the development of vaccines against emerging infectious diseases. The signing ceremony took place between Dr Jerome Kim (Director General of IVI) and Dr Richard Hatchett (CEO of CEPI) at the CEPI office in London, UK.
Under the terms of the renewed CEPI-IVI Implementing Partnership Agreement, IVI will provide technical services for CEPI-funded projects, leveraging IVI's expertise and capabilities at their headquarters in Korea and around the world to help accelerate vaccine development against pathogens with epidemic or pandemic potential, and in support of CEPI's 100 Days Mission, a goal to reduce the time taken to develop safe and effective vaccines against pathogens with pandemic potential to 100 days. To this end, IVI will support CEPI across a variety of projects, including providing strategic, technical and scientific support for clinical development and manufacturing of vaccines, standards and assay development, and capacity-building initiatives that strengthen local resources to help establish or improve research preparedness and emergency evidence generation for future outbreaks.
The ongoing CEPI-IVI partnership builds upon previous successful collaborations between the two organizations.
We are delighted to reaffirm our partnership with IVI, following several years of fruitful collaboration to advance vaccine R&D for better global health. As our organisations continue to work toward the joint goal of accelerating the development of safe, effective and accessible vaccines against emerging infectious diseases, this ongoing partnership will play an important role in our work to ensure the world is better prepared to fight future outbreaks.
Our partnership with CEPI is an exemplary model of a public-private partnership with the vision, support, and capabilities to move innovative vaccine technology from need to impact. Following years of collaboration across laboratory research, epidemiology, vaccine clinical development, and clinical research preparedness for diseases such as COVID-19, chikungunya, and MERS, we are proud and looking forward to expanding IVI's role as an implementing partner to advance vaccines against emerging and epidemic infectious diseases.
—ENDS—
About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI's work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).
During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale and access. These programmes leverage the rapid response platforms developed by CEPI's partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX.
CEPI's 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other betacoronaviruses, and create a "library" of vaccine candidates for use against known and unknown pathogens. The plan is available at https://endpandemics.cepi.net.
Follow our news page for the latest updates. Follow us via @CEPIvaccines, @DrRHatchett, and on LinkedIn.
To read more about how the world can work together to #endpandemics, check out DISEASE X — The 100 Days Mission to End Pandemics, by CEPI's Chief Scientific Writer Kate Kelland, available here at Bookshop.org. All author proceeds go to the World Health Organization Foundation's COVID-19 Response.
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI's current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world's first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.
Media
CEPI
E: [email protected]
T: +44 7387 055214
IVI
E: [email protected]
P: +82 2 881 1386
Mobilising Brazil’s manufacturing might to support vaccine production in the Global South
New trial to assess if mpox vaccination works after virus exposure
